CUSIP No.           67060M 107

2

CUSIP No.        67060M 107

3

CUSIP No.      67060M 107

4

This Amendment No. 7 to Schedule 13D (“Amendment No. 7”) relates to the shares of common stock, $0.001 par value per share (the “Common Stock’) of Nutrastar International Inc., a Nevada corporation (the “Company”), which has its principal executive offices at 4/F Yushan Plaza, 51 Yushan Road, Nangang District, Harbin 150090, People’s Republic of China.

This Amendment No. 7 is being filed jointly by Accretive Capital Asia, Accretive Capital Management and Mr. Fearon (collectively, the "Reporting Persons") to amend and supplement the Items set forth below of the Schedule 13D previously filed with the Securities and Exchange Commission (the "SEC") on December 6, 2012, as amended on July 9, 2013, January 2, 2014, June 3, 2014, July 22, 2015, November 25, 2015 and February 3, 2016 (collectively, "Schedule 13D"). Except as provided herein, this Amendment No. 7 does not modify any of the information previously reported on the Schedule 13D.

Item 3 of Schedule 13D is hereby amended and supplemented by the following:

Funds used for the acquisition of 323,535 shares of Common Stock is pursuant to a Note and Common Stock Purchase Agreement (the “Agreement”) dated January 29, 2016, between Mr. Fearon and the Company where the Company borrowed $50,000 from Mr. Fearon. Under the terms of the Agreement, the Note bears interest at 12% per annum, payable monthly, and maturing on October 29, 2016 and, in further consideration for the loan, a grant of 323,535 shares of restricted common stock were issued to Mr. Fearon. For more information about the Agreement, please refer to the Company’s Current Report on Form 8-K filed on February 3, 2016.

Funds used for the acquisition of 4,205,953 shares of Common Stock is pursuant to the Agreement dated January 29, 2016, between Accretive Capital Partners and the Company where the Company borrowed $650,000 from Accretive Capital Partners. Under the terms of the Agreement, the Note bears interest at 12% per annum, payable monthly, and maturing on October 29, 2016 and, in further consideration for the loan, a grant of 4,205,953 shares of restricted common stock were issued to Accretive Capital Partners. For more information about the Agreement, please refer to the Company’s Current Report on Form 8-K filed on February 3, 2016.

On July 27, 2016, Accretive Capital Partners, LLC (“Accretive Capital Partners”), of which Accretive Capital Management is the manager (and Mr. Fearon is the managing partner of Accretive Capital Management), transferred all of the securities of the Company held by it to Accretive Capital Asia.

Item 4 is hereby amended and restated as follows:

The Reporting Persons acquired the securities of the Company that they beneficially own for the investment purposes as they believe that the Common Stock was undervalued and represented an attractive investment.

On January 25, 2012, Accretive Capital Partners acquired 45,000 shares of Series A Preferred Stock from ARC China, Inc., a Shanghai corporation (“ARC China”), through a private transaction. In connection with the share purchase, ARC China assigned its right to cause the Company to appoint or elect one person designated by ARC China to the Company's Board of Directors under certain Securities Purchase Agreement, dated May 27, 2010, by and among the Company and certain investors, to Accretive Capital Partners. Accretive Capital Partners thereafter designated Mr. Fearon as the candidate to be elected to the Company’s Board of Directors. For more information about the Securities Purchase Agreement, please refer to the Company’s Current Report on Form 8-K filed on June 3, 2010.

5

On December 23, 2013, Accretive Capital Partners purchased 2,750 shares of Series A Preferred Stock and 25,000 shares of Common Stock through a private transaction with Joshua Kurtzig.

On December 23, 2013, Accretive Capital Partners purchased 700,000 shares of Common Stock at a purchase price of $1.40 per share through a private transaction with New Zealand WAYNE’s Investment Holdings Co., Ltd.

On December 23, 2013, Accretive Capital Partners purchased 75,000 shares of Common Stock at a purchase price of $1.30 per share through a private transaction with Robert Tick.

On June 23, 2014, Accretive Capital Partners purchased 300,000 shares of Common Stock at a price of $1.40 per share through a private transaction with New Zealand WAYNE’s Investment Holdings Co., Ltd.

On November 16, 2015, Accretive Capital Partners acquired 430,517 shares of Common Stock in connection with the Agreement and in further consideration for the loan between the Company and Accretive Capital Partners.

On November 16, 2015, Mr. Fearon acquired 18,718 shares of Common Stock in connection with the Agreement and in further consideration for the loan between the Company and Mr. Fearon.

On January 29, 2016, Accretive Capital Partners acquired 4,205,953 shares of Common Stock in connection with the Agreement and in further consideration for the loan between the Company and Accretive Capital Partners.

On January 29, 2016, Mr. Fearon acquired 323,535 shares of Common Stock in connection with the Agreement and in further consideration for the loan between the Company and Mr. Fearon.

On July 27, 2016, Accretive Capital Partners, of which Accretive Capital Management is the manager (and Mr. Fearon is the managing partner of Accretive Capital Management), transferred all of the securities of the Company held by it to Accretive Capital Asia.

The Reporting Persons intend to review their investment in the Company on a continuing basis. Subject to applicable legal requirements, the Reporting Persons may purchase additional securities or dispose of all or a portion of their securities of the Company from time to time in open market or private transactions, depending on their evaluation of the Company’s business, prospects and financial condition, the market for the Company’s securities, other developments concerning the Company and general economic, money market and stock market conditions.

While the Reporting Persons hold their stake for investment purposes, the Reporting Persons or its representatives may continue to conduct discussions from time to time with management and the board of directors of the Company, and may conduct discussions with other stockholders of the Company, prospective acquirers of the Company, or other relevant parties, in each case, relating to matters that may include the strategic plans, strategy, assets, business, financial condition, operations, and capital structure of the Company.

In addition to the foregoing, without limitation, the Reporting Persons may engage in discussions with management, the board of directors, stockholders of the Company, prospective acquirers of the Company, and other relevant parties or take other actions through their representatives concerning any extraordinary corporate transaction (including but not limited to a merger or acquisition) or the business, operations, assets, strategy, future plans, prospects, corporate structure, board composition, management, capitalization, dividend policy, charter, bylaws, corporate documents, agreements, de-listing or de-registration of the Company. The Reporting Persons expect to conduct discussions with other stockholders, potential acquirers of the Company, and other relevant parties regarding financial or strategic acquisitions of or joint ventures with the Company or other similar arrangements. There is no assurance that these discussions would lead to a definitive transaction.

6

The Reporting Persons may also engage the Company, other stockholders of the Company, prospective acquirers of the Company, or other relevant parties in discussions that may include one or more of the other actions described in subsections (a) through (j) of Item 4 of Schedule 13D.

Other than as described above in this Item 4 or as would occur upon completion of any of the actions discussed herein, the Reporting Persons do not have any present plan or proposal relating to or that would result in any of the events or matters described in part (a) through (j) of Item 4 of Schedule 13D.

Item 5 is hereby amended and restated as follows:

(a) – (b) As of the date of this Amendment No. 7, Accretive Capital Asia beneficially owns 6,905,826 shares of the Common Stock, including 668,500 shares of Common Stock issuable upon conversion of 47,750 shares of Series A Preferred Stock at any time, at the option of Accretive Capital Asia, on a 1-for-14 basis, representing approximately 26.97% of the outstanding shares of the Common Stock of the Company. However, the conversion of Series A Preferred Stock is subject to Section 4(f) of the Certificate of Designation setting forth the designation and rights of the Series A Preferred Stock, under which, the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of Series A Preferred Stock held by Accretive Capital Asia cannot be more than 9.99% . By virtue of his direct and indirect control of Accretive Capital Management and Accretive Capital Asia, Mr. Fearon is deemed to have sole voting and dispositive powers with respect to the shares of Common Stock beneficially owned by Accretive Capital Asia, as to which Accretive Capital Management and Accretive Capital Asia are deemed to have shared voting and dispositive powers.

In addition, Mr. Fearon individually owns 451,453 shares of Common Stock representing 1.76% of the outstanding shares of the Company, as to which he has sole voting and dispositive powers.

(c)       Except as described above in Item 4 of this Amendment, the Reporting Persons did not effect any transactions in the Company’s securities within the past 60 days.

7

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

8